Zarife Sahenk
Physician · Nationwide Children's Hospital
Credentials: · · ·
History
- 1977–1981
Neurodevelopmental Disabilities
- 1973–1977
Neurology
Research
Eteplirsen for the treatment of Duchenne muscular dystrophy
Annals of Neurology · 2013 · 617 citations
Dystrophin immunity in Duchenne's muscular dystrophy
New England Journal of Medicine · 2010 · 503 citations
Myoblast transfer in the treatment of Duchenne's muscular dystrophy
New England Journal of Medicine · 1995 · 401 citations
84 papers
- JK
11 papers
9 papers
9 papers · 2 as a fellow
7 papers · 3 as a fellow
- AA
6 papers · 5 as a fellow
- SA
6 papers
5 papers
Grants
- 2018–2022
Neurotrophin-3 Gene Therapy for Charcot-Marie-Tooth 1A
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $1.4M · Research Inst Nationwide Children's Hosp
- 2010–2017
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy
National Institute of Child Health and Human Development · U54
Project lead · $763.8K · Research Inst Nationwide Children's Hosp
- 2014–2016
Lentivirus Transduced Tolerogenic Dendritic Cells For The Treatment Of CIDP
National Institute of Neurological Disorders and Stroke · R21
Contact PI · $313.8K · Research Inst Nationwide Children's Hosp
- 2010–2015
NT-3 Gene Therapy to Improve Peripheral Nerve Function Induced by Genetic Defect
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $1.5M · Research Inst Nationwide Children's Hosp
Clinical trials
- 2027–2030
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
Principal investigator · Withdrawn · Phase 1, Phase 2
Nationwide Children's Hospital
- 2020